Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, adding:
”Choosing the right anticoagulant for acute venous thromboembolism (VTE) often comes down to balancing efficacy with bleeding risk.
A recent international randomized trial compared apixaban and rivaroxaban, two of the most commonly used direct oral anticoagulants for treating acute pulmonary embolism and proximal deep-vein thrombosis.
Study design
- 2,760 patients with acute symptomatic VTE
- Randomized 1:1 to apixaban or rivaroxaban
- 3-month treatment period
- Primary endpoint: clinically relevant bleeding (major plus clinically relevant non-major bleeding)
Dosing
- Apixaban: 10 mg BID for 7 days – 5 mg BID
- Rivaroxaban: 15 mg BID for 21 days – 20 mg daily
Key results
Clinically relevant bleeding:
- Apixaban: 3.3%
- Rivaroxaban: 7.1%
- Relative risk: 0.46 (95% CI 0.33–0.65, P < 0.001)
This represents ~54% lower risk of clinically relevant bleeding with apixaban over the 3-month treatment period.
Mortality remained very low in both groups
- Apixaban: 0.1%
- Rivaroxaban: 0.3%
Takeaway
Among patients with acute VTE, apixaban demonstrated a significantly lower bleeding risk compared with rivaroxaban, while maintaining similar overall safety outcomes.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger, for the COBRRA Trial Investigators
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 30, 2026, 18:36Amina Ammar: Evaluating Rivaroxaban Dosing Alignment Across Cockcroft–Gault and eGFR Equations
-
Jul 30, 2026, 18:11Tobias Tritschler: Evaluating Timing, Translation and Preparedness in COVID-19 Anticoagulation Management
-
Jul 30, 2026, 16:05Peter Zdziarski: Today is Chronic Disease Awareness Day
-
Jul 30, 2026, 15:50Ahmad Gharehbaghian: New Blood Transfusion Centers Open in Iran
-
Jul 30, 2026, 15:32Can We Better Protect Hospitalized Patients With Obesity From Venous Thromboembolism? – RPTH Journal
-
Jul 30, 2026, 15:162025 Platelet Transfusion Thresholds: When to Transfuse and When Not to Transfuse – Chokri Ben Lamine
-
Jul 30, 2026, 14:34Flora Peyvandi: Genetics of Early-Onset Coronary Artery Disease in Iranians
-
Jul 30, 2026, 14:22Stéphanie Forté: New Evidence Strengthens the Case for Hydroxyurea in HbSC Disease
-
Jul 30, 2026, 14:09Hilal Ahmad: New Guidelines for Pediatric Ischemic Stroke Management